Evidence map›Paper›PMID 35083135›Full record

ArticleFrontiers in oncology2021

Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models.

Adrián Mosquera Orgueira, Miguel Cid López, Andrés Peleteiro Raíndo, Aitor Abuín Blanco, Jose Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Laura Bao Pérez, Roi Ferreiro Ferro, Carlos Aliste Santos and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Adrián Mosquera OrgueiraUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Miguel Cid LópezUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Andrés Peleteiro RaíndoUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Aitor Abuín BlancoUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Jose Ángel Díaz AriasUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Marta Sonia González PérezUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Beatriz Antelo RodríguezUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Laura Bao PérezUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Roi Ferreiro FerroUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Carlos Aliste SantosUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Manuel Mateo Pérez EncinasUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Máximo Francisco Fraga RodríguezUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Claudio CerchioneIstituto Tumori della Romagna Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy.
Pablo MozasHospital Clinic de Barcelona, Barcelona, Spain.
José Luis Bello LópezUniversity Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.
Universidade de Santiago de Compostela · ESInstituto de Investigación Sanitaria de Santiago · ESServicio Gallego de Salud · ESHospital Clínic de Barcelona · ESIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular Lymphoma (FL) has a 10-year mortality rate of 20%, and this is mostly related to lymphoma progression and transformation to higher grades. In the era of personalized medicine it has become increasingly important to provide patients with an optimal prediction about their expected outcomes. The objective of this work was to apply machine learning (ML) tools on gene expression data in order to create individualized predictions about survival in patients with FL. Using data from two different studies, we were able to create a model which achieved good prediction accuracies in both cohorts (c-indexes of 0.793 and 0.662 in the training and test sets). Integration of this model with m7-FLIPI and age rendered high prediction accuracies in the test set (cox c-index 0.79), and a simplified approach identified 4 groups with remarkably different outcomes in terms of survival. Importantly, one of the groups comprised 27.35% of patients and had a median survival of 4.64 years. In summary, we have created a gene expression-based individualized predictor of overall survival in FL that can improve the predictions of the m7-FLIPI score.

Indexed as

folliculargene expressionlymphomamachine learningsurvival

Identifiers

PMID35083135
PMCPMC8784530
OpenAlexW4206673004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.